Cargando…

A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience

PURPOSE: Fluoropyrimidine-based combination chemotherapy, in combination with either oxaliplatin or irinotecan, has demonstrated efficacy and tolerability in treatment of advanced colorectal cancer (ACC). MATERIALS AND METHODS: Between January 2006 and December 2007, a total of 478 ACC patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Soon Il, Park, Se Hoon, Lim, Do Hyoung, Park, Keon Woo, Lee, Jeeyun, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138923/
https://www.ncbi.nlm.nih.gov/pubmed/21811425
http://dx.doi.org/10.4143/crt.2011.43.2.96
_version_ 1782208413402398720
author Lee, Soon Il
Park, Se Hoon
Lim, Do Hyoung
Park, Keon Woo
Lee, Jeeyun
Park, Joon Oh
Park, Young Suk
Lim, Ho Yeong
Kang, Won Ki
author_facet Lee, Soon Il
Park, Se Hoon
Lim, Do Hyoung
Park, Keon Woo
Lee, Jeeyun
Park, Joon Oh
Park, Young Suk
Lim, Ho Yeong
Kang, Won Ki
author_sort Lee, Soon Il
collection PubMed
description PURPOSE: Fluoropyrimidine-based combination chemotherapy, in combination with either oxaliplatin or irinotecan, has demonstrated efficacy and tolerability in treatment of advanced colorectal cancer (ACC). MATERIALS AND METHODS: Between January 2006 and December 2007, a total of 478 ACC patients were treated with combination chemotherapy in first-line settings. Combination therapies included: 5-fluorouracil, folinic acid plus oxaliplatin (FOLFOX, n=172), 5-fluorouracil, folinic acid plus irinotecan (FOLFIRI, n=95), capecitabine plus oxaliplatin (XELOX, n=155), and capecitabine plus irinotecan (XELIRI, n=56). FOLFOX and FOLFIRI were repeated every 2 weeks, whereas XELOX and XELIRI were repeated every 3 weeks until occurrence of disease progression or unacceptable toxicity, or until a patient chose to discontinue treatment. RESULTS: The median age was 58 years (range, 19 to 84 years) and the median chemotherapy durations for FOLFOX, FOLFIRI, XELOX, and XELIRI were 4.9, 4.5, 5.7, and 5.4 months, respectively. Combination chemotherapy regimens were generally well tolerated. The estimated median progression-free-survival (PFS) for all patients was 6.8 months (95% confidence interval, 6.3 to 7.3 months). No statistically significant difference in PFS was found among regimens used as first-line chemotherapy. Sixty percent (n=290) of patients received second or further lines of therapy after failure. CONCLUSION: Fluoropyrimidine-based combination chemotherapy regimens appear to be equally active and tolerable as first-line therapy for ACC.
format Online
Article
Text
id pubmed-3138923
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-31389232011-08-02 A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience Lee, Soon Il Park, Se Hoon Lim, Do Hyoung Park, Keon Woo Lee, Jeeyun Park, Joon Oh Park, Young Suk Lim, Ho Yeong Kang, Won Ki Cancer Res Treat Original Article PURPOSE: Fluoropyrimidine-based combination chemotherapy, in combination with either oxaliplatin or irinotecan, has demonstrated efficacy and tolerability in treatment of advanced colorectal cancer (ACC). MATERIALS AND METHODS: Between January 2006 and December 2007, a total of 478 ACC patients were treated with combination chemotherapy in first-line settings. Combination therapies included: 5-fluorouracil, folinic acid plus oxaliplatin (FOLFOX, n=172), 5-fluorouracil, folinic acid plus irinotecan (FOLFIRI, n=95), capecitabine plus oxaliplatin (XELOX, n=155), and capecitabine plus irinotecan (XELIRI, n=56). FOLFOX and FOLFIRI were repeated every 2 weeks, whereas XELOX and XELIRI were repeated every 3 weeks until occurrence of disease progression or unacceptable toxicity, or until a patient chose to discontinue treatment. RESULTS: The median age was 58 years (range, 19 to 84 years) and the median chemotherapy durations for FOLFOX, FOLFIRI, XELOX, and XELIRI were 4.9, 4.5, 5.7, and 5.4 months, respectively. Combination chemotherapy regimens were generally well tolerated. The estimated median progression-free-survival (PFS) for all patients was 6.8 months (95% confidence interval, 6.3 to 7.3 months). No statistically significant difference in PFS was found among regimens used as first-line chemotherapy. Sixty percent (n=290) of patients received second or further lines of therapy after failure. CONCLUSION: Fluoropyrimidine-based combination chemotherapy regimens appear to be equally active and tolerable as first-line therapy for ACC. Korean Cancer Association 2011-06 2011-06-30 /pmc/articles/PMC3138923/ /pubmed/21811425 http://dx.doi.org/10.4143/crt.2011.43.2.96 Text en Copyright © 2011 by the Korean Cancer Association http://creativecommons.org/licenses/by-nc/3.0 This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Soon Il
Park, Se Hoon
Lim, Do Hyoung
Park, Keon Woo
Lee, Jeeyun
Park, Joon Oh
Park, Young Suk
Lim, Ho Yeong
Kang, Won Ki
A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience
title A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience
title_full A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience
title_fullStr A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience
title_full_unstemmed A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience
title_short A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience
title_sort retrospective study of first-line combination chemotherapy in advanced colorectal cancer: a korean single-center experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138923/
https://www.ncbi.nlm.nih.gov/pubmed/21811425
http://dx.doi.org/10.4143/crt.2011.43.2.96
work_keys_str_mv AT leesoonil aretrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT parksehoon aretrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT limdohyoung aretrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT parkkeonwoo aretrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT leejeeyun aretrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT parkjoonoh aretrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT parkyoungsuk aretrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT limhoyeong aretrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT kangwonki aretrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT leesoonil retrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT parksehoon retrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT limdohyoung retrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT parkkeonwoo retrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT leejeeyun retrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT parkjoonoh retrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT parkyoungsuk retrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT limhoyeong retrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience
AT kangwonki retrospectivestudyoffirstlinecombinationchemotherapyinadvancedcolorectalcancerakoreansinglecenterexperience